Hydrochloride granisetron transdermal patches, hydrochloride granisetron tablets and Sancuso transdermal patches pharmacokinetic characteristics and security in healthy subjects

Trial Profile

Hydrochloride granisetron transdermal patches, hydrochloride granisetron tablets and Sancuso transdermal patches pharmacokinetic characteristics and security in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Granisetron (Primary) ; Granisetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top